U.S. Health System Needs "Innovation Criteria" To Guide Reimbursement, J&J Exec Says
This article was originally published in The Pink Sheet Daily
"The health care system cannot afford to continue to invest in all innovations at the same rate," Biopharmaceuticals Group Chairman Joseph Scodari said.
You may also be interested in...
Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.